Gluten-free diet has been shown to improve gut symptoms in patients with celiac disease and also in adult patients with diagnosis of Irritable Bowel Syndrome (Rome III criteria). Antibodies to native gliadin (AGA) have been suggested as a potential diagnostic marker of response to GFD. However, this has not been tested in a prospective study in IBS patients. Identification of predictors of a symptomatic response to GFD within the IBS population would improve the clinical management of these patients. The purpose of this study is to evaluate the effect of gluten-free diet on gastrointestinal symptoms and gut motility in patients with Irritable Bowel Syndrome stratified according to their antigliadin antibodies status. Additional purposes include investigating effects gluten free diet may have on other parameters: * Improvement of mood * Quality of life and general well-being * Changes in gut microbiota
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Enrollment
75
Gluten-free diet- Instructions provided by a dietitian
Farncombe Institute
Hamilton, Ontario, Canada
Improvement on gastrointestinal symptoms
Decrease \>2 points IBS Birmingham score
Time frame: 4 weeks
Normalization of gastrointestinal transit
(SHAPE 25-50 radiopaque markers)
Time frame: 4 weeks
Improvement anxiety and/or depression
Decrease \>2 points Hospital anxiety and depression (HAD) score
Time frame: 4 weeks
Improvement somatization
Decrease somatization scores (PHQ15)
Time frame: 4 weeks
Improvement quality of life and well-being
Decrease in the psychological general well-being (PGWB) score
Time frame: 4 weeks
Changes in gut microbiota
changes in microbial composition
Time frame: 4 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.